XML 100 R82.htm IDEA: XBRL DOCUMENT v3.20.4
Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax $ 16,659.0 $ 16,887.0 $ 18,271.0
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax 0.5 14.0 [1] (4.0) [1]
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax 834.0 822.0 959.0
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax [2] 130.0 $ (51.0) $ (12.0)
Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]      
Derivative [Line Items]      
Gain (Loss) on Derivative Instruments, Net, Pretax [1] $ 0.0    
[1] Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. [The [positive] impact from these derivatives recognized under revenues was $1 million, $14 million and ($4) million, partially offset by $0 million, $X million and $X million negative impact recognized under cost of sales in the years ended December 31, 2020, 2019 and 2018, respectively]. [To be updated] The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
[2] Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.